Infectious disease research


Allina Health commits itself to the treatment and prevention of all forms of infectious diseases to foster up-to-date patient care and advance health care practices.

Our research

Through interdisciplinary collaboration with various departments and organizations, we are able to explore new possibilities for the treatment and prevention of infectious diseases. Our work with diseases such as COVID-19, lyme disease, influenza, septicemia, Respiratory Syncytial Virus (RSV), Human Immunodeficiency Virus (HIV) and Hepatitis B/C has made great strides toward better infectious disease management.

While our research expands across a variety of diseases, it focuses on viral illnesses such as Human Immunodeficiency Virus (HIV) and Hepatitis B/C. Through this focus, we have found immense success with several research efforts, specifically within the HIV population. These studies include our REPRIEVE, GS-4030 and LIFE studies. Our investigators' impassioned research and lectures in this area stretch from clinical initiatives here at home to philanthropic efforts abroad.

Our principal investigator, Dr. Frank Rhame, has been working with infectious diseases for over 45 years. His passion for patients has taken him all over the world. From providing training to medical officers in Uganda for over 10 years to giving lectures across the globe—his work is a reflection of Allina Health’s patient-driven research.

We create new and progressive research through partnerships and collaboration with various disciplines, both within Allina Health and outside health care groups.

Patients and study participants

Before a research study begins, our clinic’s committed staff takes great care in screening any patient who is interested in study participation.

Patients must give their consent to participate and any involvement in a research study is strictly voluntary. During any phase of a study, patients have the right to revoke their consent. Prior to a study’s commencement, research volunteers will need to meet certain criteria including factors such as age, gender and health status. These criteria are to ensure the safety of all participants and make certain that researchers are able to assist and provide necessary information to volunteers.

Participating in a clinical trial provides a unique avenue toward new treatment, medicine and practices. This is an opportunity that expands beyond personal improvement and assists in the advancement of the treatment and prevention of infectious diseases.

Our research team

Frank Rhame, MD

Lara Freyder, Manager

Cynthia Miller, RN, Nurse Researcher

Cecely Hoyt, MPH, Research Specialist

Sarah Hauglie, CNA, Clinical Research Assistant

Providers and study sponsors


  • Novartis
  • Gilead
  • Glaxo Smith Kline
  • Merck
  • Division of AIDS (DAIDS)
  • National Heart, Lung, and Blood Institute (NHLBI)
  • Regeneron
  • Center for Disease Control and Prevention (CDC)
  • ViiV
  • Pfizer
  • Roche
  • Cepheid
  • Janssen
  • Basilea
  • Sanofi


  • University of Minnesota
  • Hennepin County Medical Center (HCMC)
  • Allina Health Minneapolis Heart Institute (AHMHI)
  • Patient-Centered Outcomes Research Institute (PCORI) / Greater Plains Collaborative (GPC)


  • Frank Rhame, MD
Current clinical trials